Occudo Quantitative Strategies’s NovoCure NVCR Stock Holding History

Occudo Quantitative Strategies’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,511	Closed	-$234K	–	1073
2023 Q3	$234K	Buy	+14,511	New	+$418K	0.03%	751
2023 Q2	–	Sell	-6,664	Closed	-$401K	–	1195
2023 Q1	$401K	Buy	+6,664	New	+$533K	0.04%	574
2022 Q2	–	Sell	-15,613	Closed	-$1.29M	–	1302
2022 Q1	$1.29M	Sell	15,613 -1,734	-10%	-$128K	0.11%	299
2021 Q4	$1.3M	Buy	17,347 +3,784	+28%	+$380K	0.12%	268
2021 Q3	$1.58M	Buy	+13,563	New	+$2.05M	0.19%	135
2021 Q2	–	Sell	-2,458	Closed	-$325K	–	1005
2021 Q1	$325K	Buy	2,458 +148	+6%	+$23.4K	0.07%	465
2020 Q4	$400K	Buy	+2,310	New	+$316K	0.13%	321

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Occudo Quantitative Strategies's NVCR Position: Q4 2023 in Review

Occudo Quantitative Strategies sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 14,511 shares — an estimated $234K sold.

Occudo Quantitative Strategies first reported a position in NVCR in Q4 2020 and held it in 7 quarters. The position peaked at $1.58M in Q3 2021. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

Occudo Quantitative Strategies reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
Occudo Quantitative Strategies sold 14,511 NovoCure shares in Q4 2023, an estimated $234K.
Occudo Quantitative Strategies first reported a position in NovoCure in Q4 2020 and held it in 7 quarters.
Occudo Quantitative Strategies's NovoCure position peaked at $1.58M in Q3 2021.
219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.